Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: [ppt] + web + 0.14  Related to the article below (Last Update: 8/4/2008)

IBERIABANK Corporation Reports Improved Credit Quality
MarketWatch - Jul 22, 2008
The PowerPoint presentation may be accessed on the Company's web site, http://www.iberiabank.com, under "Investor Relations" and then "Presentations. ...IBKC
Source: Google News

[CITATION] Results 1-10 of about 26 for related: etd. caltech. edu/etd/avail...(0.14 seconds)
VD Ferguson, X Guo, V Vorperian?

[CITATION] Results 1-10 of about 28 for related: etd. caltech. edu/etd/avail...(0.14 seconds)
VD Ferguson, X Guo, V Vorperian?

[PDF] Web Appendix A Simulating Working-Land Payment Programs
P Here - ers.usda.gov
... To model hurdle rates, payments are simulated for reducing the number of Aggregate
Environmental Index points (see Web Appendix B ... X VC P X AEI AEI PPT X VC P ...
-

Powerful or Pointless? Faculty Versus Student Perceptions of PowerPoint Use in Business Education
KE James, LA Burke, HM Hutchins - Business Communication Quarterly, 2006 - bcq.sagepub.com
... attend the class when notes were posted on the Web. ... t = 4.978, p < .000), but students
rated PPT?s impact ... differ from the neutral point (t = ?0.14, p < .889 ...

Response of a benthic food web to hydrocarbon contamination -
KR Carman, JW Fleeger, SM Pomarico - Limnology and Oceanography, 1997 - JSTOR
... sedi- ments on the meiofaunal-microalgal food web of a ... the bottle, and 1 liter of
15-ppt artificial seawater ... 0.36 0.14 M. littorale 0.44 0.003 P. wellsi 0.54 ...

Long-Term Deprivation of Substance P in PPT-A Mutant Mice Alters the Anoxic Response of the Isolated … -
P Telgkamp, YQ Cao, AI Basbaum, JM Ramirez - Journal of Neurophysiology, 2002 - Am Physiological Soc
... Search for citing articles in: ISI Web of Science (5). ... group for direct comparisons
with the PPT-A mutant ... from 0.22 ? 0.04 Hz during control to 0.14 ? 0.03 Hz ...

Towards Effective Web Resources Management
WM Approach - doi.ieeecomputersociety.org
... Download [I] downloads doc, pdf, ppt, txt, log, mso or wmz files 1 ... Figure 2. CBMG
of HKWS web site ... 13.59% 0.3027 4 151 155 1.53% 0.0342 7 7 14 0.14% 0.0031 72 ...

[PDF] Web Server Performance Simulation MEng Individual Project Outsourcing Report (version 1.0. 0.16)
A Ferrier - new-destiny.co.uk
Page 1. Web Server Performance Simulation ... In order to do this, I will construct software
to enable a user to simulate an a web server (or web servers). ...

[PDF] Food web interactions in the plankton of Long Island bays, with preliminary observations on brown … -
DJ Lonsdale, EM Cosper, WS Kim, M Doall, A … - Marine ecology progress series. Oldendorf, 1996 - int-res.com
... Food web interactions in the plankton ... Stock cultures were grown in f/2 enriched Instant
Ocean pre- pared at a salinity of 30 ppt (Guillard & Ryther 1962), and ...
-

Towards Effective Web Resources Management An Empirical Study and a Web Mining Approach -
ISY Kwan - Computer and Information Technology, 2005. CIT 2005. The …, 2005 - ieeexplore.ieee.org
... Download [I] downloads doc, pdf, ppt, txt, log, mso or wmz files 1 ... Figure 2. CBMG
of HKWS web site ... 13.59% 0.3027 4 151 155 1.53% 0.0342 7 7 14 0.14% 0.0031 72 ...

Source: Google Scholar
 
 

Alimera Sciences Receives FDA Approval To Market Alaway(TM) OTC For Up To 12 Hours Of Eye Itch Relief

Article Date: 06 Dec 2006 - 0:00am (PST

Alimera Sciences Inc., an ophthalmic pharmaceutical company founded just three years ago, today announced that the U. S. Food and Drug Administration (FDA) has approved its ophthalmic solution Rx-to-OTC-switch new drug application (NDA) for Alaway(TM) (ketotifen fumarate ophthalmic solution 0.025%). Alaway(TM), a multiple action eye anti-allergic, is Alimera's first NDA submission and the first to win approval. Indicated for the temporary relief of itchy eyes, Alaway(TM) will be marketed over-the- counter with the prescription strength active ingredient found in a prescription allergy eye drop.

An estimated 40 million people cope with itchy eyes associated with pollen, ragweed, grass, animal hair and dander -- particularly during the spring and fall months. Unlike over-the-counter anti-itch eye drop products currently available, just one dose of Alaway(TM) offers eye itch relief within minutes and lasts up to 12 hours. Other over-the-counter products currently available offer no more than four hours of relief and require four doses per day. Alaway(TM), with its unique property of being both an antihistamine and a mast cell stabilizer addresses itchy eyes, the number one complaint among eye allergy sufferers.

Article continues below and (thank you)
 
"Developing Alaway(TM), submitting the application and achieving FDA approval for a three-year-old company is, indeed, an accomplishment of which Alimera is tremendously proud," said Dan Myers, president and chief executive officer of Alimera Sciences. "The FDA's approval of Alaway(TM) marks a milestone in Alimera's overall strategy to consistently deliver innovative solutions to patient needs.

Alimera initially filed the NDA for Alaway(TM) in February of this year after completing a successful clinical study that showed it to be bioequivalent to Novartis' Zaditor(R) (ketotifen fumarate ophthalmic solution 0.025%). Alaway(TM), in a 10mL bottle, is expected to be available to consumers in time to provide prescription strength relief for the spring 2007 allergy season.

About Alimera Sciences Inc.

Alimera Sciences Inc., a venture backed company, specializes in the development and commercialization of over-the-counter and prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products address both the anterior (front) and posterior (back) segments of the eye. In August 2004, Alimera Sciences unveiled Soothe(R), the market's first multi-dose, emollient-based artificial tear product, and in October 2005 initiated a Phase III clinical trial to study diabetic macular edema (DME) patients treated using Medidur(TM) with fluocinolone acetonide, the company's pharmacologic treatment for DME.

Alimera Sciences Inc.
http://www.alimerasciences.com
 

Combination Therapy Shows Improvement For Breast Cancer Patients

Giving radiation therapy and chemotherapy at the same time after a lumpectomy helps keep breast cancer from returning locally, according to a study published in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

Breast cancer widely affects women in the United States, with more than 213,000 women estimated to be diagnosed in 2006. For early-stage breast cancer, the standard treatment is a lumpectomy (surgical removal of the tumor) followed by radiation therapy to the entire breast. Doctors usually recommend chemotherapy in addition for women with invasive disease. When to give the chemotherapy - whether after surgery, but before radiation or after surgery and radiation - has been widely debated among researchers.

Cancer researchers at Yale New Haven Hospital in New Haven, Conn., and the Cancer Institute of New Jersey, New Brunswick, N.J., wanted to try to answer the question as to the proper sequencing of chemotherapy. Doctors recorded data from more than 2,000 patients over the course of nearly 25 years. Of those women, 535 patients were treated with the different sequencing of chemotherapy and radiation therapy. Patients were then grouped by how they received the treatment, 276 women received chemotherapy before radiation therapy, 106 women received radiation therapy before chemotherapy, 109 women received concurrent chemotherapy and radiation and 44 women received the "sandwich" technique of alternating chemotherapy with radiation therapy and then repeating chemotherapy.

The outcome for the women in the study was successful across the group, with 10-year overall survival at 78 percent. Doctors found that there was no significant difference in the way these combinations affected the general patient outcome, but there was a difference in where tumors could relapse. Of the 109 patients who received chemotherapy and radiation therapy at the same time, only 8 percent relapsed locally (in the conservatively treated breast) over 10 years. Of the women who received radiation therapy before chemotherapy, 13 percent had a local relapse while 22 percent of the women who had chemotherapy before radiation had a local relapse.

"It is important for doctors to test and retest combinations of treatments and how we deliver them to our patients. In this retrospective analysis, by concurrently administering chemotherapy and radiation therapy, there appears to be a benefit to selected patients in terms of local control of the breast cancer. The challenge over the next few years is to identify those patients who would best benefit from this strategy. This can best be accomplished by prospective clinical trials," said Bruce G. Haffty, M.D., lead author of the study and a radiation oncologist at Robert Johnson Wood Medical School-UMDNJ and the Cancer Institute of New Jersey, in New Brunswick, N.J.

###

For more information on breast cancer treatment options, please visit http://www.rtanswers.org/.

ASTRO is the largest radiation oncology society in the world, with more than 8,500 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

Contact: Beth Bukata
American Society for Therapeutic Radiology and Oncology
 
Google
Web www.iconocast.com